

Applicants: Iva Greenwald and Diane Levitan  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 7

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-46. (canceled)
47. (currently amended) A method for determining whether ~~a compound is capable of ameliorating Alzheimer's disease~~an agent increases presenilin activity comprising (a) ~~treating~~ introducing the agent to a transgenic Caenorhabditis elegans animal, mutants having reduced, increased or altered sel-12 activity with the compound wherein the animal exhibits an egg-laying defective (Egl) phenotype induced by partial or total loss of SEL-12 protein activity; and (b) determining whether the ~~compound agent rescues suppresses, enhances or has no effect on the Egl phenotype, of the mutant, the suppression or enhancement of the phenotype indicating that the compound is capable of ameliorating Alzheimer's diseases~~such rescue indicating that that agent increases presenilin activity.
48. (currently amended) A ~~The~~ method of claim 47, wherein the transgenic Caenorhabditis elegans mutant to be treated ~~is~~comprises the sel-12(ar171)allele(ATCC Accession No. 97292).

Applicants: Iva Greenwald and Diane Levitan  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 8

49. (currently amended) A—The method of claim 47,  
wherein the transgenic Caenorhabditis elegans ~~mutant~~  
~~to be treated~~ is comprises the sel-12(ar131)  
allele(ATCC Accession No. 97293).

50-86. (canceled)